Diabetes Drug Pricing Presentation 
STAT
FEBRUARY 8, 2024
LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.
STAT
OCTOBER 8, 2024
Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list. The FDA noted, though, that a rival drug from Novo Nordisk called Wegovy remains on the shortages list.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 6, 2023
The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering.
Digital Pharmacist
MARCH 19, 2024
From sweeping federal legislation aimed at reigning in costs to the unexpected maneuvers of drug manufacturers, the effects of these changes reverberate throughout the healthcare system. The Dynamics of Increasing Drug Prices The escalation of drug prices is a multifaceted issue, with various factors contributing to its rise.
Pharmaceutical Technology
DECEMBER 20, 2022
The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The company is expected to continue experiencing positive growth from its new immunology drugs, Skyrizi (risankizumab-rzaa) and Rinvoq (upadacitinib).
Proxsys Rx
MAY 18, 2023
The skyrocketing costs of prescription drugs It’s no secret that prescription drug prices are rising faster than the rate of inflation, forcing employers to shift more of their prescription benefit costs to their employees and families. This usually means higher deductibles, higher co-pays, and lower morale among employees.
Proxsys Rx
MARCH 23, 2023
The growing problem of prescription non-adherence According to a study published in the Annals of Internal Medicine, nearly 1/3 of all prescriptions are never filled by patients, and up to half of medications for chronic conditions like diabetes and hypertension are never taken.
Expert insights. Personalized for you.
256 
Let's personalize your content